Final-Program-ATS-2023-AP.vp

SATURDAY • MAY 20

27

12:45 Acute Cellular Rejection; Updates on Diagnosis and Management M.E. Snyder, MD, Pittsburgh, PA 1:10 Antibody Mediated Rejection; What’s New in Risk and Management? Speaker to be Announced 1:35 Biomarkers and Therapeutic Targets, PFT, BAL, Liquid Biopsy and Biologics J.L. Todd, MD, MHS, Durham, NC 2:00 Panel Discussion 2:15 Break 2:30 CLAD; Diagnosis and Management- Anything New or All Doom and Gloom? E.D. Lease, MD, Seattle, WA 2:55 Quality of Life Post Lung Transplant; How Much Are We Really Helping Our Patient With End Stage Lung Diseases? J.P. Singer, MD, MSci, San Francisco, CA 3:20 Retransplant for CLAD; Indications, Outcomes and Ethical Implications V.N. Lama, MD, MS, Ann Arbor, MI 3:45 Panel Discussion 3:58 Concluding Remarks PG8 INTERSTITIAL LUNG DISEASE: DELIVERING OPTIMAL, PATIENT CENTERED CARE R Pre-registration and additional fees required. Attendance is limited. Member: $440 In-Training Member: $255 LMIC Member: $310 LMIC In-Training Member: $180 Non-Member: $540 In-Training Non-Member: $380 Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing; Pulmonary Circulation; Pulmonary Rehabilitation 8:00 AM - 4:00 PM Target Audience This course should be broadly relevant to those who provide clinical care for patients with ILD. This will include fellows, general pulmonologists, ILD specialists, and advanced care nurses. Marriott Marquis Washington Capitol/Congress (Level M4) CLINICAL POSTGRADUATE COURSE CME Credits Available: 6

Objectives At the conclusion of this session, the participant will be able to: • better understand the indications and proper timing of referral for lung transplantation as well as optimization of patients with end stage lung disease prior to listing • understand the process of donor selection and optimization, peri-operative care of lung transplant including mechanical ventilation and ECMO support • recognize various causes of acute and chronic allograft dysfunction and how to utilize the current methods to diagnose and treat them This session will provide updates and cover important topics of lung transplant that are highly relevant to ATS attendees. The audience will learn about indications and proper referral, donor selection, operative care and complication as well as immune mediated rejections and long term outcomes of lung transplant. Chairing: C.A. Hage, MD, ATSF, Pittsburgh, PA C.M. Shaver, MD, PhD, Nashville, TN C.A. Hage, MD, ATSF, Pittsburgh, PA 8:05 Indications and Timing of Referral for Lung Transplant; Who and When? L.J. Benvenuto, MD, New York, NY 8:30 Optimization of Lung Transplant Recipients; How Can It Be Achieved? M.R. Anderson, MD, MS, Philadelphia, PA 8:55 Is My Patient Ready for Listing, Science or Art and How Can We Quantify Readiness? G.S. Dhillon, MPH, MD, Stanford, CA 9:20 Panel Discussion 9:35 Break 9:50 Donor Management and Selection; Is There a Perfect Donor for My Recipient? E. Cantu III, MD, MSCE, Philadelphia, PA 10:15 Perioperative Care of Lung Transplant, Mechanical Ventilation, ECMO and Other Critical Care Treatments J.C. Salgado, MD, Miami, FL 10:40 Primary Graft Dysfunction; Is It Just a Post-Op ALI or Much More and What Can Be Done to Minimize Its Risk? J.M. Diamond, MD, MSCE, Philadelphia, PA 11:05 Panel Discussion 11:20 Airway and Vascular Complications Mimicking Acute Rejection M.M. Crespo, MD, Philadelphia, PA 11:45 Lunch J.F. Mcdyer, MD, Pittsburgh, PA P.M. Shah, MD, Baltimore, MD 8:00 Introduction

ATS 2023 • Washington, DC